on Aspire Biopharma, Inc. (NASDAQ:PWUP)
Aspire Biopharma to Present at Emerging Growth Conference
Aspire Biopharma Holdings, Inc. is set to present at the Emerging Growth Conference on April 17, 2025. Kraig Higginson, the company's CEO, will showcase their cutting-edge drug delivery technology. The virtual presentation will include a Q&A session. Attendees can register online to access the webcast.
This announcement coincides with Aspire's initiation of a Phase 1 clinical study for their lead therapeutic candidate, a fast-acting high-dose aspirin. The trial aims to refine the drug formulation for future FDA approval.
Aspire plans to engage with the FDA following the study to continue the development of the aspirin, potentially leading to market approval for myocardial infarction treatment.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Aspire Biopharma, Inc. news